Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

669 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma.
Tovoli F, Pallotta DP, Vivaldi C, Campani C, Federico P, Palloni A, Dalbeni A, Soldà C, Lani L, Svegliati-Baroni G, Garajova I, Ielasi L, De Lorenzo S, Granito A, Stefanini B, Masi G, Marra F, Lonardi S, Brandi G, Daniele B, Auriemma A, Schiadà L, Chen R, Piscaglia F; ARTE study group. Tovoli F, et al. Among authors: masi g. Dig Liver Dis. 2024 Dec;56(12):2079-2084. doi: 10.1016/j.dld.2024.07.035. Epub 2024 Aug 20. Dig Liver Dis. 2024. PMID: 39168753 Free article.
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone A. Fornaro L, et al. Among authors: masi g. Ann Oncol. 2013 Aug;24(8):2062-7. doi: 10.1093/annonc/mdt165. Epub 2013 May 10. Ann Oncol. 2013. PMID: 23666916 Free article. Clinical Trial.
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, Michelucci A, Pfanner E, Brunetti I, Lupi C, Antoniotti C, Bergamo F, Lonardi S, Zagonel V, Simi P, Fontanini G, Falcone A. Loupakis F, et al. Among authors: masi g. Eur J Cancer. 2014 Jan;50(1):57-63. doi: 10.1016/j.ejca.2013.08.024. Epub 2013 Oct 15. Eur J Cancer. 2014. PMID: 24138831 Clinical Trial.
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Loupakis F, et al. Among authors: masi g. N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108. N Engl J Med. 2014. PMID: 25337750 Free article. Clinical Trial.
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
Casadei Gardini A, Marisi G, Scarpi E, Scartozzi M, Faloppi L, Silvestris N, Masi G, Vivaldi C, Brunetti O, Tamberi S, Foschi FG, Tamburini E, Tenti E, Ricca Rosellini S, Ulivi P, Cascinu S, Nanni O, Frassineti GL. Casadei Gardini A, et al. Among authors: masi g. Expert Opin Pharmacother. 2015;16(18):2719-25. doi: 10.1517/14656566.2015.1102887. Epub 2015 Oct 29. Expert Opin Pharmacother. 2015. PMID: 26513009 Free article.
669 results